STAT1 (Ab-727) Antibody

What is STAT1-pSer727 and what distinguishes it from other STAT1 phosphorylation sites?

STAT1 (Signal Transducer and Activator of Transcription 1) is a transcription factor that mediates cellular responses to interferons, cytokines, and growth factors. While STAT1 tyrosine-701 phosphorylation (STAT1-pY701) is essential for its dimerization and nuclear translocation, serine-727 phosphorylation (STAT1-pS727) serves a distinct regulatory function. STAT1-pS727 occurs via p38 MAPK (MAPK14) pathways and plays a crucial role in modulating STAT1's transcriptional activity without affecting its nuclear localization or DNA binding capacity . Unlike STAT1-pY701, which is absolutely required for STAT1 function, STAT1-pS727 selectively enhances certain STAT1-mediated processes, particularly in autoimmune responses, while being dispensable for others such as anti-pathogen responses .

How is STAT1-pSer727 regulated in response to different stimuli?

STAT1-pSer727 is regulated through distinct signaling pathways depending on the stimulus. In response to type II interferon (IFN-γ), STAT1 undergoes both tyrosine and serine phosphorylation . The serine phosphorylation at position 727 occurs through p38 MAPK pathways and enhances STAT1's transcriptional activity . Following bacterial lipopolysaccharide (LPS)-induced TLR4 endocytosis, STAT1 can also be phosphorylated at Thr-749 by IKBKB, which influences its binding to specific DNA sequences and regulates gene expression . This complex regulation allows STAT1 to respond differently to various stimuli, including type I interferons (IFN-α, IFN-β), growth factors, and cytokines, each leading to distinct cellular outcomes .

What experimental models have been developed to study STAT1-pSer727 function?

Researchers have developed several experimental models to study STAT1-pSer727 function, particularly the STAT1-S727A mutant model in which serine 727 is replaced with alanine, preventing phosphorylation at this site. These models include:

• B6.STAT1-S727A mutant mice crossed with autoimmune-prone B6.Sle1b mice to generate B6.Sle1b.STAT1-S727A (Sle1b.STAT1-SA) mice

• B cell-specific bone marrow (BM) chimeras to study cell-intrinsic roles of STAT1-pS727

• TLR7-accelerated B6.Sle1b.Yaa SLE disease model expressing STAT1-S727A mutant

These models have allowed researchers to dissect the specific role of STAT1-pS727 in autoimmune responses while distinguishing its function from other STAT1 activities .

What are the key specifications to consider when selecting a STAT1-pSer727 antibody?

When selecting a STAT1-pSer727 antibody for research, several critical specifications should be considered:

• Specificity: Ensure the antibody detects STAT1 only when phosphorylated at Serine 727, avoiding cross-reactivity with unphosphorylated STAT1 or other phosphorylation sites

• Host species and clonality: Available options include rabbit polyclonal and rabbit recombinant monoclonal antibodies

• Species reactivity: Confirm reactivity with your species of interest (human, mouse, rat, etc.)

• Validated applications: Verify the antibody is validated for your specific application (WB, IHC, IF, Flow Cytometry, ELISA, ICC)

• Purification method: Consider antibodies purified via sequential chromatography on phospho- and non-phospho-peptide affinity columns for enhanced specificity

The selection should be guided by your specific experimental needs and the biological context of your research question.

What experimental applications are STAT1-pSer727 antibodies validated for?

STAT1-pSer727 antibodies have been validated for multiple experimental applications:

• Western Blotting (WB): For detecting phosphorylated STAT1 protein in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing STAT1-pSer727 in tissue sections

• Immunofluorescence (IF): For cellular localization studies

• Flow Cytometry: For analyzing STAT1-pSer727 at the single-cell level

• Immunocytochemistry (ICC): For detecting STAT1-pSer727 in cultured cells

• ELISA: For quantitative analysis of STAT1-pSer727 levels

Each application requires specific optimization conditions, including antibody dilution, incubation time, and detection methods. Researchers should validate these conditions for their specific experimental systems.

What are the recommended controls when using STAT1-pSer727 antibodies?

When using STAT1-pSer727 antibodies, implementing proper controls is essential for result validation:

• Positive controls: Cell lines or tissues with known STAT1-pSer727 expression, such as IFN-γ-stimulated cells

• Negative controls:

  • STAT1-deficient cells or tissues

  • Samples treated with phosphatase to remove phosphorylation

  • Cells expressing STAT1-S727A mutant protein

• Blocking peptide controls: Using the immunizing phospho-peptide to confirm antibody specificity

• Total STAT1 detection: Running parallel assays with antibodies against total STAT1 to normalize phosphorylation levels

• Loading controls: Standard protein loading controls appropriate for your experimental system

These controls help ensure that observed signals are specific to STAT1-pSer727 and not artifacts or non-specific binding.

What is the role of STAT1-pSer727 in systemic lupus erythematosus development?

STAT1-pSer727 plays a critical role in the development of systemic lupus erythematosus (SLE) through several mechanisms:

• Promotion of autoimmune antibody-forming cell (AFC) responses: STAT1-pSer727 enhances the differentiation of B cells into AFCs that produce autoantibodies

• Enhancement of germinal center (GC) responses: Studies with B6.Sle1b.STAT1-S727A mice showed reduced frequency of GC B cells, reduced size and number of splenic GCs, and decreased Tfh cells compared to control B6.Sle1b mice

• Driving autoantibody production: STAT1-pSer727 promotes the production of autoantibodies including anti-dsDNA and anti-nucleosome antibodies, which contribute to SLE pathogenesis

• B cell-intrinsic function: Using B cell-specific bone marrow chimeras, researchers demonstrated that STAT1-pSer727 has an important B cell-intrinsic role in promoting autoimmune responses

• Lupus nephritis development: In the TLR7-accelerated B6.Sle1b.Yaa SLE disease model, the absence of STAT1-pSer727 resulted in ameliorated kidney pathology

These findings highlight STAT1-pSer727 as a potential therapeutic target for SLE treatment.

How does STAT1-pSer727 differentially regulate autoimmune versus anti-pathogen responses?

One of the most intriguing aspects of STAT1-pSer727 function is its differential regulation of autoimmune and anti-pathogen immune responses:

• Autoimmune responses: STAT1-pSer727 is crucial for autoimmune AFC and GC responses, driving autoantibody production and SLE development

• Anti-pathogen responses: In contrast, STAT1-pSer727 is not required for GC, follicular helper T (Tfh) cell, and antibody responses to various foreign antigens including pathogens

• Gut microbiota and dietary antigen responses: STAT1-pSer727 is also not required for gut microbiota and dietary antigen-driven GC and Tfh responses in B6.Sle1b mice

This differential requirement suggests that targeting STAT1-pSer727 could potentially suppress pathogenic autoimmune responses while preserving protective immunity against pathogens, making it an attractive therapeutic target with potentially fewer side effects than global immune suppression .

What experimental approaches can assess STAT1-pSer727's role in B cell responses?

To assess STAT1-pSer727's role in B cell responses, researchers can employ several experimental approaches:

• B cell-specific bone marrow chimeras: Generate chimeric mice by transferring B cell-specific STAT1-S727A bone marrow into irradiated recipients to study cell-intrinsic effects

• Flow cytometry analysis: Measure GC B cell and Tfh cell frequencies using appropriate markers

• Immunohistochemistry: Assess the size and number of germinal centers in secondary lymphoid organs

• ELISPOT assays: Quantify autoantigen-specific antibody-forming cells in spleen and bone marrow

• Serum autoantibody measurements: Determine autoantibody titers and ANA-seropositivity

• TLR7-accelerated disease models: Study the role of STAT1-pSer727 in accelerated autoimmunity contexts

• Phospho-flow analysis: Directly measure STAT1-pSer727 levels in different B cell subsets following stimulation

These approaches provide complementary information about how STAT1-pSer727 influences B cell differentiation, activation, and function in autoimmune contexts.

What are the critical factors affecting STAT1-pSer727 antibody performance in Western blotting?

Several factors can significantly impact STAT1-pSer727 antibody performance in Western blotting:

• Sample preparation:

  • Use phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Process samples quickly and maintain cold temperatures

  • Consider using SDS-PAGE with Phos-tag™ for enhanced separation of phosphorylated proteins

• Blocking conditions:

  • Use BSA rather than milk for blocking when detecting phospho-epitopes

  • Optimize blocking buffer composition to reduce background while maintaining specific signal

• Antibody dilution and incubation:

  • Determine optimal antibody concentration through titration experiments

  • Consider longer incubation times at lower temperatures (4°C overnight)

• Detection method:

  • Enhanced chemiluminescence (ECL) systems with higher sensitivity may be required

  • Consider using signal enhancers specific for phospho-protein detection

• Membrane selection:

  • PVDF membranes may provide better results than nitrocellulose for phospho-epitopes

  • Consider low-fluorescence membranes for fluorescent detection systems

Optimizing these factors can significantly improve detection of STAT1-pSer727 in Western blotting applications.

How can researchers distinguish between direct and indirect effects of STAT1-pSer727 in cellular studies?

Distinguishing between direct and indirect effects of STAT1-pSer727 requires strategic experimental design:

• Reconstitution experiments:

  • Express wild-type STAT1 or STAT1-S727A mutant in STAT1-deficient cells

  • Compare immediate early responses versus delayed responses

• Chromatin immunoprecipitation (ChIP):

  • Determine direct binding of STAT1-pSer727 to target gene promoters

  • Compare binding patterns between wild-type and S727A mutant STAT1

• RNA-seq time course analysis:

  • Identify primary versus secondary transcriptional responses

  • Compare transcriptional profiles between cells expressing wild-type STAT1 and STAT1-S727A

• Pharmacological inhibition:

  • Use specific inhibitors of STAT1-Ser727 phosphorylation (e.g., p38 MAPK inhibitors)

  • Assess immediate effects on cellular processes versus long-term outcomes

• Signaling pathway analysis:

  • Examine multiple components of signaling cascades

  • Determine which pathways are directly affected by STAT1-pSer727 versus secondary consequences

These approaches can help delineate the direct transcriptional effects of STAT1-pSer727 from its indirect influences on cellular signaling networks.

What factors should be considered when using STAT1-pSer727 antibodies in immunofluorescence studies?

When using STAT1-pSer727 antibodies for immunofluorescence studies, researchers should consider several important factors:

• Fixation and permeabilization:

  • Paraformaldehyde fixation (typically 4%) preserves phospho-epitopes

  • Test different permeabilization reagents (Triton X-100, methanol, saponin) as they can affect epitope accessibility

• Epitope retrieval:

  • Heat-induced epitope retrieval may be necessary for some tissues

  • Determine optimal pH and buffer composition for maximal signal recovery

• Antibody validation:

  • Use positive controls (IFN-γ stimulated cells) and negative controls (phosphatase-treated or STAT1-S727A expressing cells)

  • Perform peptide competition assays with the immunizing phospho-peptide

• Signal amplification:

  • Consider tyramide signal amplification for low-abundance phospho-proteins

  • Balance signal intensity with background noise

• Co-localization studies:

  • Combine with markers for cellular compartments to determine localization

  • Use total STAT1 antibodies in parallel to determine the proportion of phosphorylated protein

Optimizing these parameters helps ensure specific detection of STAT1-pSer727 and accurate interpretation of localization patterns.

How might targeting STAT1-pSer727 lead to novel therapeutic approaches for autoimmune diseases?

Targeting STAT1-pSer727 offers promising therapeutic potential for autoimmune diseases, particularly SLE, based on several key findings:

• Selective inhibition of autoimmunity: STAT1-pSer727 promotes autoimmune AFC and GC responses but is dispensable for anti-pathogen immune responses, suggesting that its inhibition could suppress autoimmunity while preserving protective immunity

• Reduced autoantibody production: Inhibiting STAT1-pSer727 could decrease autoantibody production by reducing autoimmune AFC and GC responses, addressing a key pathogenic factor in SLE

• Prevention of tissue damage: In TLR7-accelerated SLE models, the absence of STAT1-pSer727 results in ameliorated kidney pathology, suggesting that its inhibition could prevent end-organ damage

• B cell-targeted approach: Given the B cell-intrinsic role of STAT1-pSer727 in promoting autoimmunity, targeted inhibition in B cells could provide specificity while minimizing off-target effects

• Potential therapeutic strategies:

  • Small molecule inhibitors of kinases responsible for STAT1-Ser727 phosphorylation

  • Peptide-based inhibitors that interfere with STAT1-pSer727 interactions

  • RNA-based therapeutics to modulate expression of STAT1 or its regulatory kinases

These approaches offer potentially more selective therapeutic options compared to current broad immunosuppressive treatments for autoimmune diseases.

What are the current knowledge gaps regarding STAT1-pSer727 mechanisms in immune regulation?

Despite significant advances, several knowledge gaps remain regarding STAT1-pSer727's mechanisms in immune regulation:

• Kinase specificity: While p38 MAPK pathways are implicated in STAT1-Ser727 phosphorylation, the precise kinases involved may vary by cell type and stimulus context

• Transcriptional targets: The complete set of genes directly regulated by STAT1-pSer727 in different immune cell types remains to be fully characterized

• Interaction partners: The specific protein-protein interactions mediated by STAT1-pSer727 that modulate its function are not completely understood

• Temporal dynamics: The kinetics of STAT1-Ser727 phosphorylation and dephosphorylation in different immune contexts require further investigation

• Integration with other STAT1 modifications: How Ser727 phosphorylation interacts with other post-translational modifications of STAT1 (including Tyr701 phosphorylation) to fine-tune its function needs further study

• Cell type-specific functions: While B cell-intrinsic roles have been investigated, the importance of STAT1-pSer727 in other immune cell types during autoimmunity remains unclear

Addressing these knowledge gaps could further refine therapeutic strategies targeting STAT1-pSer727 in autoimmune diseases.

How can researchers optimize experimental design when studying STAT1-pSer727 in complex immune interactions?

Optimizing experimental design for studying STAT1-pSer727 in complex immune interactions requires multi-faceted approaches:

• Conditional knockout systems:

  • Use cell type-specific and inducible STAT1-S727A expression systems

  • Combine with lineage-tracing approaches to track cellular differentiation and function

• Temporal considerations:

  • Design time-course experiments to capture dynamic changes in STAT1-pSer727

  • Consider both acute responses and chronic disease development

• Multi-parameter analysis:

  • Integrate techniques such as mass cytometry or spectral flow cytometry for comprehensive immune profiling

  • Combine with phospho-specific detection to correlate STAT1-pSer727 with cellular phenotypes

• Ex vivo and in vitro validation:

  • Isolate specific cell populations from animal models for mechanistic studies

  • Validate findings from animal models in human samples when possible

• Systems biology approaches:

  • Incorporate transcriptomic, proteomic, and epigenomic analyses

  • Use computational modeling to predict network effects of STAT1-pSer727

• Physiologically relevant stimuli:

  • Use complex stimuli that mimic in vivo conditions rather than single cytokines

  • Consider the influence of tissue microenvironment on STAT1-pSer727 function